Europe Psoriasis Drugs Market Report

Europe Psoriasis Drugs Market Size

The europe psoriasis drugs market is anticipated to rise from USD 3.18 billion in 2024 to USD 5.60 billion in 2033, growing at a CAGR of 7.36%.

Psoriasis is a communicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the skin's surface. The rapid development of cells produces thick, silvery scales and makes the skin red, dry, flaky, and itchy. Currently, no permanent cure is available for the disease,

However, preventative measures can be adopted to slow down skin cells on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceutical therapies through the topical and systemic processes

These medications are administered either by applying on the skin or consumed orally or through injections that specifically block parts of the immune system by specifically targeting Tumor Necrosis Factor, Phosphodiesterase Type 4, Interleukin, among others. In Europe, approximately 3.7 million people are affected by psoriasis as per the European Federation of Pharmaceutical Industries and Associations.

The growth of the Psoriasis Drugs market is majorly driven by factors such as increasing public awareness, approval of new drugs (interleukin-17 inhibitor, Taltz - ixekizumab by Eli Lily), and a boost in psoriasis Research and Development investment. The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologic medications, and health insurance issues.

KEY MARKET PLAYERS

Prominent companies dominating the European Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).

MARKET SEGMENTATION

This research report on the European Psoriasis Drugs Market has been segmented and sub-segmented into the following categories:

By Drug Type

• Pharmaceuticals
• Biopharmaceuticals

By Route of Administration

• Topical
• Systemic
  • Oral
  • Intravenous
  • Others

By Target

• Tumour Necrosis Factor (TNF)
• Phosphodiesterase Type 4 (PDE4)
• Interleukin

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe